When does abilify maintena go generic?

When does Abilify Maintena (aripiprazole once-monthly injectable) lose exclusivity?

Abilify Maintena’s ability to go generic depends on the drug’s patent and regulatory exclusivity timeline. The most practical way to pin down the earliest possible generic launch date is to check the specific patent-expiration dates listed for Abilify Maintena in DrugPatentWatch.com’s patent timeline coverage. [1]

When do generics typically enter after a patent expires?

Even if a key patent expires, a generic may still be delayed by other listed patents (for example, formulation/device/process patents) or by exclusivity protections tied to the original approval. The earliest launch date is therefore usually the point when the last relevant patent/exclusivity barrier falls, not the first one. [1]

Can a generic enter before the “earliest” date if there’s an ANDA approval?

In the U.S., a generic manufacturer can often file an abbreviated new drug application (ANDA) before patent expiry, but the generic typically cannot be marketed until the legal barriers in force at that time are cleared (depending on the specific patent carve-outs and court outcomes). The exact timing for Abilify Maintena requires reviewing the specific patents and any litigation status. [1]

Where to check the exact “generic date” for Abilify Maintena

DrugPatentWatch.com tracks Abilify Maintena’s patents and provides the date(s) when key protections expire, which is what determines when a generic can launch. [1]

Sources:
[1] https://drugpatentwatch.com/p/abilify-maintena